Drugs with miraculous benefits require very few patients to meet bars for statistical significance
The most common are gastrointestinal: nausea (experienced by 20-40% of patients, usually diminishing over time), vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite (which contributes to therapeutic effects but can be excessive for some patients)
Additional Abbreviations, Acronyms, and Symbols (For Possible Future Inclusion in the Official Do Not Use List) II
This transporter is strongly expressed in the kidneys and, at a lower level, in trachea, bone marrow, liver, skeletal muscle, prostate, lung, pancreas, intestine, placenta, heart, uterus, spleen, spinal cord, and neurons (Pochini et al., 2013)
Studied properties The largest published research stream for retatrutide is body-weight reduction in adults with obesity